Understanding the Diagnostic Complexity

Mammary metaplastic squamous cell carcinoma is an exceptionally rare and aggressive subtype of triple-negative breast cancer (TNBC). Clinicians often face significant hurdles because this malignancy frequently mimics benign conditions, such as breast abscesses. Consequently, many patients experience diagnostic delays that can negatively impact their prognosis. This diagnostic masquerade requires a high degree of clinical vigilance, especially when an inflammatory mass does not respond to standard antibiotic therapy.

The Challenge of Chemoresistance

In a recent clinical case, a 41-year-old woman presented with what appeared to be a rapidly enlarging abscess. However, definitive biopsy eventually confirmed mammary metaplastic squamous cell carcinoma. While the patient initially underwent neoadjuvant chemotherapy with nab-paclitaxel, epirubicin, and cyclophosphamide, the tumor eventually progressed. This phenomenon illustrates a common issue with metaplastic breast cancers: they often exhibit acquired resistance to standard taxane-anthracycline regimens. Therefore, alternative strategies are frequently necessary to manage such high-risk cases effectively.

Innovative Adjuvant Strategies

After a modified radical mastectomy, clinicians administered adjuvant dose-dense capecitabine. This decision was inspired by the findings of the SYSUCC-001 trial. This trial demonstrated that metronomic capecitabine maintenance can significantly improve disease-free survival in patients with early-stage TNBC. In this specific case, the patient remained recurrence-free during the follow-up period. Furthermore, this outcome suggests that capecitabine might offer a viable treatment path for metaplastic variants, although further large-scale investigation is still required.

Managing Mammary Metaplastic Squamous Cell Carcinoma in Clinical Practice

Early identification remains the cornerstone of effective management. Physicians should prioritize histological confirmation via biopsy for any rapidly enlarging breast mass, even if it mimics an infection. Additionally, multidisciplinary coordination between oncologists and surgeons is vital to navigate the complexities of chemoresistance and surgical intervention. Because this cancer subtype is notoriously refractory to conventional treatments, personalized therapy based on emerging trial data, such as metronomic chemotherapy, may provide new hope for improved survival rates.

Frequently Asked Questions

Why does mammary metaplastic squamous cell carcinoma often look like an abscess?

This cancer often presents as a rapidly enlarging, inflammatory mass with central necrosis. These features clinically and radiologically resemble the presentation of a common breast abscess, which frequently leads to initial misdiagnosis.

What is the significance of the SYSUCC-001 trial for this case?

The SYSUCC-001 trial showed that one year of metronomic capecitabine significantly improved 5-year disease-free survival in triple-negative breast cancer patients. This provided the clinical rationale for using capecitabine as an adjuvant treatment in this high-risk case.

Can standard chemotherapy treat this type of breast cancer?

While some patients show an initial response, mammary metaplastic squamous cell carcinoma is often refractory to standard anthracycline and taxane-based regimens. Many cases develop acquired resistance, necessitating surgical intervention and alternative adjuvant therapies.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Tianqing Y et al. Mammary metaplastic squamous cell carcinoma: a case report. J Med Case Rep. 2026 Feb 07. doi: 10.1186/s13256-025-05818-7. PMID: 41654984.

Wang X, et al. Effect of Capecitabine Maintenance Therapy vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021;325(1):50-58. doi:10.1001/jama.2020.23370.

Hussain M, et al. Metaplastic squamous cell carcinoma of the breast – A rare case report. Asian J Oncol. 2023;9:7. doi: 10.25259/ASJO_19_2022.